SGLT-2 inhibitors and high-dose acarbose as potential high-risk combinations for ketosis and ketoacidosis in Asian patients with T2DM：A case seriesWei Qiang1MD, Fei Yang1, 2MM, Ling Liu1, 3BS, Ruiqing Dong1BS, Yushi Sun1MD, Ahona Mondal , Hui Guo1*MD1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, P. R. China.2Department of Endocrinology, the First Affiliated Hospital of Xi’an Medical University, Xi’an 710077, P. R. China.3Department of Endocrinology, Chang Qing Oil Field Worker’s Hospital, Xi’an 710201 Xi’an 710061, P. R. China.